"FDA approval of a multicenter investigational new drug application has cleared away regulatory obstacles that stood in the way of definitive trials to establish the clinical efficacy of a PET imaging agent that measures cell proliferation in cancerous tumors.Molecular imaging researchers have touted F-18-labeled 3'-deoxy-3'-fluorothymidine (FLT) for the potential complementary role it could play with FDG for cancer imaging. "
Complete article here-
No comments:
Post a Comment